Navigation Links
SCOLR Pharma, Inc. Announces Final Closing of Private Placement
Date:6/30/2011

BOTHELL, Wash., June 30, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC: SCLR) today announced that it has closed the second and final tranche of its previously-announced private placement of its 8% Senior Secured Convertible Debentures due 2013 (the "Debentures").  The Company raised a total of $1,190,200 in the offering.  The Company intends to use the net proceeds for working capital and other general corporate purposes.

Stephen J. Turner, President and Chief Executive Officer, said: "The completion of this offering will allow us to continue to focus on the development of our nutritional business and on our efforts to secure licensing or partnership support for our pharmaceutical products.  We are making good progress in placing our nutritional products on retail shelves and this capital will enable us to be even more aggressive in those efforts."

This second tranche consisted of the sale of an additional $189,000 principal amount of Debentures.  The Debentures, together with accrued and unpaid interest, are convertible at the option of the holders into shares of the Company's common stock at a conversion price equal to $0.05 per share of common stock.  Beginning after the date that is six months from the issuance of the Debentures, the Company may cause mandatory conversion of the Debentures following the continuance for 30 consecutive days of certain conditions, including maintenance of a volume weighted average trading price on each day within such 30 day period of $0.25 per share of common stock.  The Debentures bear interest of 8% per annum, compounded quarterly, and are secured by all the Company's assets.  The Company may, at any time and from time to time, upon 10 days prior notice to the holders, pay in cash all or a portion of the accrued and unpaid interest on the Debentures, or may cause conversion of such accrued and unpaid interest in connection with any mandatory conversion of the Debentures.


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
6. SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
7. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
8. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
9. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
10. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... plant, stool and other challenging microbial nucleic acid ... Protein Extraction Kit, for extraction of pure protein ... protein world coincides with the 20 th ... growing innovation capabilities. (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ...
(Date:6/19/2013)... CLEVELAND , June 19, 2013   NineSigma ... announced that a year following its launch, NineSights.com ... and a focal point for the worldwide community of ... to climate and environmental sustainability experts, NineSights stands out ... broad range of scientific and technical disciplines, all vetted ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Today DuPont ... young people to become leaders in the greatest challenge ... billion people in 2050. Borel spoke at the ... Conference in Atlanta, about urgent need for students to ... are local, science-based, sustainable and reached in collaboration with ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2
... Purpose , ... this series describes an LC/MS/MS method for the simultaneous determination ... FK-506), Sirolimus (SIR, aka Rapamycin) and Everolimus (EVE, aka RAD-001) ... robust hardware configuration and shows to be fast and simple, ...
... , ... As the study of protein biomarkers increases in ... protein pathway information and discovery-based proteomics experiments. Even larger numbers of ... gene expression studies or other genomic information. , ...
... Purpose , ... non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is of significant ... metabolism variability. To be of practical use, it is essential ... fast and easy to perform, with minimal sample preparation, and ...
Cached Biology Technology:A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 2A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 3A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 4A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 5Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 2Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 3Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 4Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 5A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 2A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 3A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 4
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical and medical ... launch of a new open access journal, GeoResJ ... , Elsevier,s earth and planetary science journals portfolio has ... to provide a forum for rapid publication of top ... will be co-edited by six Executive Editors, each covering ...
(Date:6/18/2013)... the University of Calgary,s Faculty of Medicine have discovered ... from harmful bacteria. Platelets, a component of blood typically ... specific bacteria, and upon detection, seal it off from ... published in Nature Immunology this week, provide ... , "The science community has known that platelets do ...
(Date:6/18/2013)... environmental engineer has been awarded a $394,300 grant ... water quality and flow in the new facilities ... Kruzic, UT Arlington associate professor of civil engineering, ... add monochloramine to the water in an effort ... stations and pipelines. Adding monochloramine is widely practiced ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2
... orchids have been found to rely on a wide ... of the soil instead of producing their own organic ... the open access journal BMC Biology , also ... and Mlanie Roy, from the Centre d,Ecologie Fonctionnelle et ...
... Carnegie Mellon University have developed an analytical technique to ... disease syndromes such as diabetes, asthma and cancer, which ... Rather than searching one at a time for genetic ... as in most conventional approaches, the Carnegie Mellon scientists ...
... Water striders, the familiar semi-aquatic bugs gliding across the ... allows them to walk on water. This was not ... evolution of a unique arrangement of the legs, with the ... of Ecology and Evolutionary Biology have discovered the gene behind ...
Cached Biology News:Carnegie Mellon develops innovative method to detect genetic causes of complex diseases 2
... for quick and reproducible immunoprecipitation (IP) by using ... more reproducible than regular IPs, which are problematic ... without disrupting the agarose bed. The binding of ... reversible, and elution of the immune complex can ...
... Kit (V2), 2 x 11K will ... of many thousands of yeast genes ... biological processes. Each microarray contains sequences ... from the S288C strain of Saccharomyces ...
... require screening through a huge volume ... data from normal biologic diversity. The ... available to help better manage the ... inherent to biomarker discovery. The CiphergenExpress ...
... Immunoprecipitation kit allows a rapid and ... active FLAG-tagged protein. The immunoprecipitation is ... is a highly specific monoclonal antibody ... use of affinity resin allows an ...
Biology Products: